Abstract
Prostate cancer is the most common cancer amongst men worldwide and major cause of cancer death. Current treatments of primary prostate tumors are initially effective, however, 25% of the patients develop metastatic disease. Once the cancer has acquired resistance to Androgen Deprivation Therapy, Castration Resistant Prostate Cancer (CRPC) occurs. At this stage, highly aggressive prostate cancer cells may have spread throughout the body and can form incurable metastases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
